
Annual report 2025
added 03-31-2026
Xtant Medical Holdings EBITDA 2011-2026 | XTNT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Xtant Medical Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.5 M | -7.85 M | -6.98 M | -5.46 M | -2.52 M | 1.33 M | -2.2 M | -3.28 M | -8.18 M | -1.2 M | -5.43 M | -5.08 M | -7.9 M | -4.54 M | -5.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 M | -8.18 M | -3.5 M |
Quarterly EBITDA Xtant Medical Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.24 M | 5.42 M | - | -3.08 M | -2.45 M | -2.46 M | - | -2.88 M | -991 K | -1.1 M | - | -1.5 M | -1 M | -1.55 M | - | -404 K | -191 K | 370 K | - | 2.42 M | 766 K | -678 K | - | 1.63 M | 996 K | 108 K | - | 3.51 M | 966 K | -71 K | - | 2.75 M | -2.18 M | -496 K | - | 3.65 M | 1.53 M | -583 K | - | -2.48 M | -936 K | -1.5 M | - | -752 K | -986 K | -1.02 M | - | -1.76 M | -1.47 M | -1.03 M | - | 790 K | 55.9 K | -1.06 M | - | -762 K | 42 K | -1.64 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.42 M | -3.08 M | -200 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
753 M | $ 176.57 | 5.81 % | $ 13.2 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.2 | 2.14 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 32.98 | 6.42 % | $ 1.52 B | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 38.21 | 4.2 % | $ 5.69 K | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
10.7 M | $ 24.38 | 2.52 % | $ 206 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.13 | 0.61 % | $ 259 M | ||
|
Globus Medical
GMED
|
757 M | $ 91.75 | 1.9 % | $ 12.4 B | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.12 | 1.48 % | $ 872 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | ||
|
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.36 | -1.29 % | $ 126 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.62 | 2.46 % | $ 38.6 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.8 | 1.34 % | $ 351 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.36 | 5.18 % | $ 1.13 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 81.8 | 1.21 % | $ 47.8 B | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 53.19 | -2.25 % | $ 1.56 B | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.86 | 1.64 % | $ 1.13 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.54 | 2.25 % | $ 735 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.75 | -0.81 % | $ 180 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.11 | 7.78 % | $ 18.8 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 87.21 | 2.42 % | $ 3.03 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.86 | 0.63 % | $ 372 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
LENSAR
LNSR
|
-21 M | $ 5.66 | 0.49 % | $ 67.7 M | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 88.33 | 2.17 % | $ 114 B |